论文部分内容阅读
目的探讨CT动态增强检查评估埃克替尼治疗非小细胞肺癌(NSCLC)的疗效及临床应用价值。方法回顾性分析经病理证实的晚期NSCLC患者经分子靶向药物埃克替尼治疗前后的CT动态增强检查资料及临床资料,将患者按照RECIST标准分为缓解组和未缓解组,测量并比较两组治疗前1 w内及治疗后1个月病灶CT动态增强检查结果。结果分析测量45例患者,其中缓解组26例,未缓解组19例;两组患者治疗前病灶密度及强化程度无统计学差异(P>0.05);缓解组患者治疗后病灶密度及强化程度均减低(P<0.05);未缓解组治疗后CT密度及强化程度较治疗前略增高,但差异无统计学意义(P>0.05)。缓解组治疗后病灶密度及强化程度均低于未缓解组(P<0.05)。结论 NSCLC经过埃克替尼治疗后定量分析病灶密度变化及强化程度可以为疗效评估提供参考。
Objective To evaluate the efficacy and clinical value of CT dynamic contrast enhancement in the evaluation of Icitinib in the treatment of non-small cell lung cancer (NSCLC). Methods We retrospectively analyzed the CT dynamic enhancement data and clinical data of patients with advanced non-small cell lung cancer (NSCLC) confirmed by pathology before and after treatment with imatinib. The patients were divided into remission group and non-remission group according to RECIST standard. Within 1 w before treatment and 1 month after treatment, CT dynamic enhanced examination results. Results Analysis and measurement of 45 patients, of which 26 cases of remission group, 19 cases of non-remission group; two groups of patients before treatment no significant difference in density and intensity (P> 0.05); remission group after treatment, the lesion density and degree of enhancement (P <0.05). The density and degree of enhancement of CT in non-remission group were slightly higher than those before treatment, but the difference was not statistically significant (P> 0.05). The lesion density and degree of enhancement in the remission group were lower than those in the remission group (P <0.05). Conclusion Quantitative analysis of focal density changes and intensification of NSCLC after treatment with imatinib can provide a reference for the evaluation of the curative effect.